This funding opportunity supports scientific research utilizing data from expanded access programs for investigational drugs or biological products targeting intermediate size populations of ALS patients who are not eligible for ongoing clinical trials. Research areas include prevention, diagnosis, mitigation, treatment, or cure of ALS. The award requires a U01 clinical trial mechanism and aims to advance understanding and therapeutic options for ALS.
Eligible applicants include a wide range of U.S. entities such as independent school districts, tribal organizations, various government levels, nonprofits, for-profit organizations, and institutions of higher education. Specific eligibility details are provided in the funding announcement.
